Welcome to our dedicated page for Cavitation Technologies SEC filings (Ticker: CVAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how a green-tech micro-cap converts patents into revenue isn’t easy. Cavitation Technologies’ 10-K is packed with reactor specifications, licensing footnotes, and oilseed price sensitivities, while each 10-Q recalibrates R&D spend and partnership milestones. Add in Form 8-K updates on pilot projects and insider trades and the research pile grows fast. If you’ve ever googled “Cavitation Technologies insider trading Form 4 transactions” or searched for the “Cavitation Technologies quarterly earnings report 10-Q filing,” you know the challenge.
Stock Titan solves it. Our AI ingests every submission to EDGAR within seconds and delivers Cavitation Technologies SEC filings explained simply. You’ll receive Cavitation Technologies Form 4 insider transactions real-time, concise snapshots of each Cavitation Technologies annual report 10-K simplified, and alerts the moment a Cavitation Technologies 8-K material events explained hits the wire. Interactive dashboards surface which patents drove revenue, where cash burn accelerated, and how risk factors evolved—turning understanding Cavitation Technologies SEC documents with AI into a five-minute task.
Need deeper context? Drill into the Cavitation Technologies proxy statement executive compensation to benchmark management pay, or review Cavitation Technologies executive stock transactions Form 4 for buying patterns ahead of new reactor contracts. Side-by-side Cavitation Technologies earnings report filing analysis lets you track margin gains from biodiesel clients across multiple periods. Every filing—10-K, 10-Q, 8-K, S-1 and more—is indexed, summarized, and updated in real time, so you can move from raw disclosure to decisive insight without wading through 300 pages of technical detail.
Cavitation Technologies (CVAT)$3,000 from a short‑term equipment rental. Operating expenses were $252,000, driving a loss from operations of $249,000. Interest expense rose to $9,000 after reconciling its SBA EIDL loan, resulting in a net loss of $258,000.
Cash used in operations was $219,000, leaving $30,000 in cash at quarter‑end. Total assets were $60,000 against total liabilities of $249,000, producing a stockholders’ deficit of $(189,000). The company had 289,156,340 common shares outstanding as of
Cavitation Technologies, Inc. (CVAT) reported fiscal year results showing limited revenue and material operating losses. Revenue for the period was $165,000 while cost of revenue was $1,207,000, producing a gross loss of $1,042,000. Total operating expenses were $1,152,000, including $1,057,000 of general and administrative expenses, resulting in a loss from operations of $987,000. The company recorded an $880,000 gain on patent assignment which was collected in full. As of June 30, 2025 the company had an accumulated deficit of $26,960,000 and management disclosed substantial doubt about the company’s ability to continue as a going concern, while stating available cash to sustain operations through December 2025. Significant concentration: 98% of revenue derived from Desmet Belgium. Shares outstanding totaled 289,156,340.
FAQ
What is the current stock price of Cavitation Technologies (CVAT)?
What is the market cap of Cavitation Technologies (CVAT)?
